FT-8225

**FT-8225** is a preclinical, liver-targeted **small-molecule fatty acid synthase inhibitor** being developed by **Forma Therapeutics** for the treatment of **nonalcoholic steatohepatitis**. Fatty acid synthase drives de novo lipogenesis in the liver, and FT-8225 has been described as a next-generation, potent inhibitor designed for liver-focused distribution, with the therapeutic goal of reducing hepatic fatty acid synthesis and liver fat accumulation in NASH. Publicly available information is limited, and no brand name, detailed chemical identity, or clinical-stage human efficacy data appear to be available from the cited sources.